Introduction
Myotonic dystrophy type 1 (DM1) is an autosomal dominant inherited disease that affects many tissues. In skeletal muscle, this condition leads to weakness, atrophy, and myotonia. 1 In addition to skeletal muscle symptoms, patients with DM1 develop arrythmias and cardiomyopathy in the heart, neurological abnormalities, and insulin resistance. DM1 is caused by a mutation in the dystrophia myotonica protein kinase (DMPK) gene, which results in an expansion of CTG trinucleotide repeats within its 3′ UTR.
2,3 CTG expansions are highly unstable and vary in length in normal individuals from 5 to 35 repeats. In patients with DM1, the length of CTG expansions, which correlates with the severity of clinical symptoms, varies from 50 to several thousand repeats.
Development of DM1 therapy requires elucidation of the molecular mechanisms by which CTG repeats lead to DM1 pathology. Studies have established that CTG repeats lead to DM1 pathology by causing the accumulation of mutant DMPK mRNA transcripts containing an expanded array of CUG repeats that target RNA-binding proteins, thereby changing their activities and altering RNA homeostasis in DM1 cells. [4] [5] [6] [7] [8] The most studied RNA-binding proteins affected by CUG repeats are CELF1 (also known as CUGBP1) and MBNL1. CUGBP1 is a member of the family of CUGBP and ELAV-like factors, whereas MBNL1 belongs to the muscleblind-like (MBNL) family of proteins. [9] [10] [11] The mutant CUG repeats primarily cause two toxic events in DM1 cells. First, the aggregation of mutant DMPK transcripts, possibly due to disruption of their subsequent processing, 11, 12 can lead to sequestration of MBNL1 proteins, thereby reducing their splicing activity 11, 13 ( Fig. 1) increase CUGBP1 stability, leading to elevated levels of this protein in DM1 cells 14, 15 ( Fig. 1) . This stabilization is mediated by an increase in PKC-mediated phosphorylation of CUGBP1 and its subsequent binding to soluble CUG repeats. 14, 16 However, these mutant CUG repeats also disrupt CUGBP1 phosphorylation by other kinases. CUGBP1 contains a number of serine and threonine residues that regulate its activity and intracellular localization. Ser28 is normally phosphorylated by Akt to control the nuclear-cytoplasmic distribution of CUGBP1. 17 Another important phosphorylation site is Ser302, which is located within the spacer between RNA-binding domains 2 and 3. Ser302 phosphorylation, which is mediated by cyclin D3-dependent kinase 4 (CDK4), 17 promotes CUGBP1 binding to eukaryotic translation initiation factor 2α (eIF2α) and the subsequent association of CUGBP1 with polysomes. [17] [18] [19] Because of its positive role in activating the translation of several mRNAs, encoding p21, HDAC1, MEF2A, and cyclin D1, phospho-Ser302 CUGBP1 was designated as CUGBP1 ACT . Although CUGBP1 ACT binds to eIF2α, it does not affect global translation.
We found that a significant proportion of CUGBP1 in DM1 cells is un-phosphorylated at Ser302. 17 In contrast to the phosphorylated form, un-phosphorylated Ser302 CUGBP1 binds to inactive (phospho-Ser51) eIF2α, thereby forming the inactive CUGBP1 REP -eIF2α
complex. This repressor complex is localized within stress granules (SGs) to trap mRNAs and delay their translation. 17, 20 We found that one CUGBP1 target, MRG15, which encodes a protein, involved in DNA repair and chromatin remodeling, is bound by CUGBP1 REP in DM1 cells, leading to reduced MRG15 protein levels. 17 These data showed that CUGBP1 REP may repress the translation of many additional mRNAs in cytoplasmic aggregates or SGs, and that Ser302 phosphorylation of CUGBP1 by cyclin D3-CDK4 may act to switch the function of CUGBP1 from repressor to activator of translation. Interestingly, both forms of CUGBP1 are elevated in DM1. In addition to regulating translation, CUGBP1 controls mRNA splicing and stability. [17] [18] [19] [21] [22] [23] [24] Therefore, elevation of CUGBP1 ACT in DM1 may increase the translation of some mRNAs and change the splicing and stability of CUGBP1 targets.
Our recently published work showed that the increase in CUGBP1
REP in DM1 cells is due to elevated levels of activated GSK3β 25 . Consistent with this, GSK3β levels are also increased in the skeletal muscle of HSA LR mice, which express tracks of 250 CUG repeats within the 3′ UTR of human skeletal actin and is commonly used model of CUG repeat RNA mediated pathology in DM1. 5, 25 GSK3β has many substrates, including cyclin D3. 26 25 Moreover, treatment of HSA LR mice with lithium or TDZD-8 significantly reduced variability in myofiber size ( Fig. 2A-C) , as well as the number of central nuclei in HSA LR muscle 25 ( Fig. 2D) . Based on these data, we concluded that the elevated GSK3β is the third major toxic event in DM1 pathogenesis (Fig. 1) .
Initially, we expected that deregulation of the GSK3β-cyclin D3-CDK4-CUGBP1 pathway may be responsible for muscle atrophy in DM1. However, treatment with lithium and TDZD-8 also reduced myotonia in HSA LR mice. 25 Thus, it is possible that the correction of CUGBP1 activity may not only "normalize" the translational activity of Figure 1 . toxic events caused by mutant cuG repeats in dm1 cells and possible therapeutic approaches for their correction. mutant cuG repeats cause three toxic molecular events: (1) sequestration of mBnl1, (2) higher levels of cuGBP1, leading to elevation of the active form of cuGBP1 (cuGBP1 Act ), and (3) elevation of active GSK3β, which reduces cyclin d3 and converts a portion of cuGBP1
Act to cuGBP1 reP . thus, both cuGBP1 forms are elevated in dm1. reduced mBnl1 and increased cuGBP1
Act lead to deregulation of mrnA splicing, translation, and stability. Futhermore, increased cuGBP1 reP may reduce mrnA translation in stress granules. taken together, these molecular changes lead to myotonia, weakness, and muscle atrophy. Administration of GSK3β inhibitors reduces dm1 muscle histopathology, weakness, and myotonia similar to degradation of mutant cuG repeats by AOns.
CUGBP1, but also its splicing activity. This correction may lead to the correction of the splicing of one myotonia-associated target of CUGBP1, the chloride channel. 23 Although we found that lithium converts CUGBP1 REP into CUGBP1 ACT in HSA LR muscle, further investigation is necessary to determine whether the GSK3β-cyclin D3-CDK4 pathway plays a major role in reducing myotonia in DM1 mice or whether GSK3β inhibition affects other pathways in these mice. Taken together, we found that GSK3 inhibitors reduce DM1 pathology in HSA LR mice similar to the degradation of mutant CUG repeats by antisense oligonucleotides (AONs) [27] [28] [29] ( Fig. 1) .
Our initial experiments in which 6-mo-old HSA LR mice were treated with GSK3 inhibitors were based on protocols using short treatment durations, specifically 2-7 d for TDZD-8 or 2 weeks for lithium. 25 We noticed that grip strength increased and that myotonia was reduced in the treated mice immediately after treatment. However, once treatment was completed, HSA LR mice developed muscle weakness again. These results suggest that, to maintain "normalized" grip strength in adult HSA LR mice, GSK3 inhibitors must be administered continuously if the treatment protocols tested in our recent study are used. 25 In contrast, myotonia in these mice remained lower for several weeks after cessation of treatment. 25 The mechanisms responsible for the long beneficial effect of the GSK3 inhibitors on myotonia in HSA LR mice remain to be studied. Interestingly, the effects of these inhibitors on grip weakness were more pronounced in 6-week-old HSA LR mice. Treatment of 6-week-old HSA LR mice with TDZD-8 for 1 week significantly increased the grip strength in these mice when evaluated at 3 mo of age. 25 These data suggest that inhibition of GSK3β in HSA LR mice at a pre-symptomatic age may be beneficial to reducing the incidence of DM1 pathology in adult HSA LR mice.
Conclusions
In summary, our study found increased levels of GSK3β in the skeletal muscle of DM1 patients and HSA LR mice. 25 This alteration seems to be a key event in DM1 pathology because GSK3 inhibitors can reduce dysfunctional muscle pathology in the DM1 mouse model. It remains to be determined whether GSK3β plays a role in the development of other DM1 symptoms, such as insulin resistance and defects in cardiac and neurological functions. Studies have demonstrated that GSK3β is increased in other conditions, including type 2 diabetes mellitus. 30 Therefore, elevated GSK3β may contribute to the development of insulin resistance in DM1. Since GSK3 inhibitors are used to treat neurological disorders such as bipolar disease, 30 these compounds may also improve neurological dysfunction in patients with DM1 in addition to correcting skeletal muscle defects.
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